ulation of homocysteine-induced MMP-9 by ERK1/2 pathway.
calcium signaling; protein kinase C; Src; G protein-coupled receptor; nonreceptor tyrosine kinase; protein Gi; protein Gq; protein tyrosine kinase 2; microvascular endothelial cell; cardiovascular remodeling MATRIX METALLOPROTEINASES (MMPs) are members of a family of Zn 2ϩ -containing endoproteinases that share structural domains but differ regarding substrate specificity. MMPs also differ in their cellular sources and inducibility. Increased activity of MMPs has been implicated in numerous disease processes, including tumor cell metastasis, arthritis, periodontal diseases, atherosclerosis, and cardiac diseases (19) . Remodeling of the ECM during the development and progression of cardiac diseases depends largely on MMPs, especially MMP-9 (11, 32, 33, 36) .
Elevated plasma levels of homocysteine (Hcy) are an important independent risk factor for the development of cardiovascular diseases, stroke, thrombosis, and dementia (14) . Hcy induces endocardial endothelial cell dysfunction (28, 29) and impairs microvascular endothelial cell (MVEC) function in vivo (40) . Because these effects are mediated in part by Hcy-induced MMP-9 expression (17) , it is possible that Hcy might alter the expression of tissue inhibitors of metalloproteinase (TIMPs), which results in abnormal MMP activity (31) . MMP-9 has been implicated as a key effector in Hcy-induced vascular remodeling and atherosclerosis. For example, increased MMP-9 activity has been reported in macrophages isolated from patients with hyperhomocysteinemia leading to atherosclerosis (16) . Furthermore, Hcy induces the activation of MMP-9, which is regulated in part by TIMP-1 in cultured MVECs (37) .
Activation of MMP-9 is important in the process of vascular remodeling, but the upstream regulatory pathways that control the expression and secretion of MMP-9 are less well understood. MMP-9 contains activator protein (AP)-1 sites in its gene promoter region (13, 41) . Because AP-1 transcriptional activity is specifically regulated by MAPK, we hypothesized that MAPK is involved as an upstream trigger in MMP-9 regulation.
MAPKs are a family of serine/threonine kinases that regulate the diversity of cellular activities. Three major classes have been described: ERKs, JNKs, and p38 MAPK (12) . One of the ubiquitous intracellular signaling mechanisms is the ERK pathway. Two major isoforms of ERK, p44 (ERK1) and p42 (ERK2), have been identified in mammalian systems. ERK activation is reported to be involved in the receptor activation of multiple heteromeric G proteins, including both pertussis toxin (PTX)-sensitive protein G␣ i/o and PTX-insensitive protein G␣ q (15, 39) . The major pathway involved in ERK1/2 phosphorylation in a variety of cell types requires the activation of all isoforms of Raf by binding to the GTP-bound form of Ras, and MEK is the only commonly recognized substrate (21, 25) .
The present work was conducted to characterize the Hcyinduced ERK signaling pathway and its possible involvement in MMP-9 regulation in cultured MVECs. We report herein that Hcy triggered G protein-coupled receptors (GPCRs), which instigated signal transduction involving PTKs, Ca 2ϩ -dependent PKC, and oxidative stress transduction pathways, leading ultimately to ERK activation. Furthermore, we present evidence that Hcy-induced MMP-9 was regulated by the ERK1/2 signaling pathway.
MATERIALS AND METHODS
Chemicals. The antibody against phosphorylated ERK1/2 (p44/42) was obtained from Cell Signaling Technology (Beverly, MA). ERK2, MMP-9, PTK2, SRC2, and ␤-actin, and PKC-␣ MAbs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase (HRP)-conjugated antibody was obtained from Cappel Laboratories (Durham, NC). MEK inhibitors PD-98059 and U0126, phorbol 12,13-dibutyrate (PDBu), PMA, thapsigargin (Tg), Gö6976, and PTX B were purchased from Calbiochem (La Jolla, CA). ATP, N-acetylcysteine (NAC), SOD, D,L-homocysteine, L-cysteine, folate, fura-2 AM, ionomycin, BAPTA-AM, genistein, staurosporine, and gelatin were obtained from Sigma (St. Louis, MO).
Cell culture and treatments. Human heart MVECs were procured from Cambrex (Walkersville, MD) and cultured in endothelial basal medium 2 supplemented with growth factors as described in the supplier's protocol and 12% (vol/vol) heat-inactivated FCS maintained at 37°C in a 95% O 2-5% CO2 humidified atmosphere. MVECs were used at passages 8-13, grown to near confluence, and serum starved overnight before being treated with the indicated reagents for Western blot analysis, cytosolic Ca 2ϩ concentration ([Ca 2ϩ ]i) was measured, and gelatin zymography was performed. Serum-starved cells were pretreated for 30 min with 50 M PD-98059, 40 M U0126, 1 M staurosporine, 1 M Gö6976, 1 g/ml PTX B, 200 M genistein, and 1 M Tg before 30-min treatment with 10 M Hcy, unless otherwise indicated. Pretreatment (24 h) with 100 nM PDBu was used to downregulate PKC, whereas 30-min pretreatment with PDBu was used to activate PKC. Where indicated, serum-starved cells were pretreated for 30 min with folate (100 M), PD-98059, U0126, NAC (50 M), SOD (2,500 U/ml), ionomycin (1 M), ATP, and BAPTA-AM (30 M) before Hcy treatment.
Assay of MMP-9 activity using gelatin zymography. MMP-9 activity in cultured endothelial cells was measured as described previously (39) with some modifications. After treatment, the culture medium was collected and centrifuged at 14,000 rpm for 20 min at 4°C to remove cellular debris. The supernatant was concentrated 40-fold using a Minicon filter (Millipore, Billerica, MA) with a 15-kDa cutoff pore diameter. Conditioned medium was used to access MMP-9 activity. Protein concentration was assayed using the Bradford method (5), and the samples were mixed with equal volumes of 2ϫ SDS sample buffer. The samples were incubated at room temperature for 5 min and electrophoresed on 7.5% SDS-PAGE gels containing 2 mg/ml gelatin as a substrate at constant voltage. After electrophoresis, the gels were rinsed in renaturation buffer (2.5% Triton X-100) on a shaker for 30 min to remove SDS and then incubated overnight at 37°C in a water bath in activation buffer composed of (in mM) 50 Tris ⅐ HCl, pH 7.4, and 5 CaCl2. Gels were stained using 0.5% Coomassie blue R-250 for 2 h, followed by appropriate destaining. To confirm that the digested bands were caused by Ca 2ϩ -dependent protease, replicate gels were developed in Ca 2ϩ -free buffer containing 25 mM EDTA. MMP activity was detected as a white band on a dark blue background and quantitated densitometrically using Un-Scan-It software (Silk Scientific, Orem, UT).
Measurement of [Ca 2ϩ ]i. [Ca 2ϩ ]i levels were measured as described previously (30) . Human MVECs were cultured on glass coverslips until they reached 80% confluence. The cells were then washed with PBS, preincubated in fura-2 AM loading buffer (in mM: 110 NaCl, 5.5 KCl, 25 NaHCO3, 0.8 MgCl2, 0.4 KH2PO4, 0.33 Na2HPO4, 20 HEPES, and 1.2 CaCl2) for 10 min, and then loaded with 5 M fura-2 AM dye for 30 min in the dark at 37°C. Fura-2 AM-loaded cells were washed to remove unbound fura-2 AM before treatment. Fluorometric reading was conducted using a Fluorolog-2 spectrofluorometer (Spex Industries, Edison, NJ) at 37°C with fluorescence (F) measured at 340/380-nm excitation and 510-nm emission. [ Triton X-100, and 1 EGTA) and freshly prepared inhibitors (1 mM PMSF, 1 g/ml leupeptin, 200 M sodium orthovandate, and 1 g/ml aprotinin) were added to each well. Plates were scraped on ice, and the supernatant containing cytosolic protein was collected and centrifuged at 14,000 g for 20 min at 4°C, and resolved by SDS-PAGE on 10% polyacrylamide gels and blotted onto a polyvinylidene difluoride membrane. After being transferred, blots were washed with Trisbuffered saline (TBS) for 5 min at room temperature and incubated in blocking buffer for 1 h at room temperature. The blots were then incubated with the indicated primary antibodies [appropriate dilutions in 5% BSA-1ϫ TBS with 0.1% Tween 20 (TBST)] overnight at 4°C using gentle agitation. The blots were washed three times (8-min wash each time) with TBST and incubated with HRP-conjugated secondary antibody (1:3,000 dilution in 5% BSA-TBST). After being washed, the proteins of interest were detected using an ECL plus kit (Amersham Biosciences, Piscataway, NJ). The membranes were then stripped using 0.2 M NaOH solution for 30 min at room temperature and reprobed for total proteins. Band densities were normalized to the untreated controls and presented as percentage changes as indicated.
Statistical analysis. Statistical analysis was performed using an unpaired Student's t-test for comparison between control, Hcy, and other pharmacological treatment groups. P Ͻ 0.05 was considered statistically significant. All results are averages Ϯ SE of at least three different experiments.
RESULTS

Hcy activates ERK1/2.
To determine time-and dose-dependent responses of Hcy-induced ERK activation, we cultured MVECs with different doses of Hcy for different intervals. ERK activation was dose-and time-dependent (Fig. 1, A and B). Maximal ERK phosphorylation was observed at 30 min with 10 M Hcy supplementation. In subsequent experiments, we used one concentration (10 M) and one time point (30 min).
ERK1/2 phosphorylation by Hcy occurs via a MEK-dependent pathway. The inhibitors of MEK (PD-98059 and U0126) were used to investigate whether Hcy activated ERK via MEK. PD-98059 exerted its inhibitory effect by binding directly to the inactive form of MEK after blocking its activation by Raf. However, U0126 does not affect MEK phosphorylation but directly inhibits MAPK activation by MEK1. Both PD-98059 and U0126 blocked ERK activation significantly (Fig. 2) . In the control MVECs, basal levels of ERK phosphorylation were not affected significantly when either of the inhibitors was used alone. These results confirm the effectiveness of both inhibitors in blocking the activation of ERK via a MEK-dependent pathway.
Characterization of ERK pathway. Pretreatment of cells with PTX (1 g/ml; 20 min) completely repressed the Hcyinduced Ca 2ϩ transients and ERK activation (Fig. 3) . This suggests that Hcy-induced ERK activation occurs via GPCRs. Receptor and nonreceptor PTKs initiate the events of the ERK signaling pathway. Pretreatment of the cells with genistein (200 M; 20 min), an inhibitor of PTKs, abrogated Hcyinduced ERK phosphorylation (Fig. 3) . This finding suggested a role for PTKs in Hcy-induced ERK activation.
Folate therapy is known to ameliorate the pathological effects of Hcy. Pretreatment of the cells with folate (200 M) for 30 min significantly blocked the Hcy-induced Ca 2ϩ mobilization and ERK phosphorylation (Fig. 4) . Interestingly, this reduction in ERK activation was MEK dependent. It is well known that Hcy induces the production of reactive oxygen species (ROS) and oxidative stress in a variety of cell types. We sought to determine the role of Hcy-induced ROS production and oxidative stress in ERK activation. Incubation of the cells with SOD and NAC before Hcy treatment repressed ERK phosphorylation (Fig. 4) . To determine the importance of the essential chemical structure of Hcy (thiol group) on the activation of ERK, a structural analog of Hcy, L-cysteine was used. Serum-deprived cells, when incubated with L-cysteine ( , cells were exposed to ionomycin (1 M) for 30 min, which led to ERK activation (Fig. 6A) . Incubating the cells with Tg (1 M) for 15 min increased the ERK activation, which subsequently was repressed by treatment with genistein and BAPTA-AM (Fig. 6B) . The findings from our Hcy-related Ca 2ϩ dynamics studies with different pharmacological agents supported activation of ERK induced by Ca 2ϩ store depletion, which takes place through the PTK pathway.
To further determine the mechanism for ERK activation by Hcy, inhibitors and downregulators of PKC were used. Incubation of MVECs with PMA and PBDu (100 nM) for 30 min led to ERK activation (Fig. 7) . Pretreatment with staurosporine (1 M) for 30 min repressed ERK phosphorylation (Fig. 7A) . To validate the role of PKC in the Hcy-induced ERK signaling pathway, cells were incubated with PBDu for 24 h to downregulate PKC and were checked for PKC-␣ and ERK activation. Incubation of the cells with PBDu (24 h) before Hcy treatment abrogated ERK activation and PKC-␣ expression (Fig. 7C) . These results specifically support the role of PKC in Hcy-induced ERK activation. PKC-␣ belongs to a conventional group of PKCs and therefore depends on Ca 2ϩ for its activation. Incubation of cells with a selective inhibitor of Ca 2ϩ -dependent PKC, Gö6976 (1 M), for 30 min abrogated Hcy-induced ERK phosphorylation (Fig. 7B) . These results suggest a role for Ca 2ϩ -dependent PKC in the Hcy-induced ERK signaling pathway. Bottom gel: ERK activation was measured in cell lysates using Western blot analysis for phosphorylated ERK1/ERK2, i.e., p44 and p42, respectively (pERK1/2); top gel: membranes were stripped and reprobed with ERK2 MAb for total ERK2. Density of the bands was determined and quantified for ERK1/2 activation as shown in histograms (increase relative to control). B: serum-starved MVECs were treated with 10 M Hcy for the indicated times. Bottom gel: ERK1/2 phosphorylation was measured in cell lysates; top gel: membranes were reprobed for total ERK2. Density of the bands was determined and quantified for ERK1/2 activation (increase relative to control) as shown in histograms. Bars represent averages Ϯ SE from 3 different experiments. #P Ͻ 0.05 vs. control. 
Hcy-mediated MMP-9 is regulated by ERK involving PKC and oxidative stress transduction pathways.
Hcy is known to induce MMP-9 in cultured MVECs. Hcy-mediated MMP-9 activity and expression were abrogated in cells incubated with PD-98059 (MEK inhibitor) (Fig. 8, A and C) , which suggested the possible involvement of the ERK signaling pathway in Hcy-mediated MMP-9 regulation. Pretreatment with a PKC inhibitor, staurosporine, abrogated Hcy-mediated MMP-9 induction (Fig. 8, B and D) . These results provide evidence for the involvement of PKC in Hcy-induced MMP-9 regulation.
Pretreatment of the cells with NAC abrogated Hcy-induced activation of MMP-9 (Fig. 8, A and C) , which suggested the possible involvement of oxidative stress in MMP-9 regulation. In control experiments, the treatment of MVECs with 0.1% DMSO had no effect on MMP-9 induction.
DISCUSSION
A large body of evidence suggests that the increased activity of MMPs, particularly MMP-9, is involved in ECM remodeling and leads to cardiovascular disease. Previous studies conducted at our laboratory showed that Hcy induced MMP-9 in MVECs. However, the signaling pathways that regulate MMP-9 induction are poorly understood. For the first time, we have demonstrated that Hcy-induced MMP-9 is regulated by the ERK1/2 (MAPK) signaling pathway and have extended the understanding of the mechanisms involved in Hcy-mediated ERK activation in cultured MVECs. In MVECs, ERK activation is maximal at 10 M Hcy at 10 -30 min (Fig. 1) . Our observations are in accord with the findings reported in previous studies (6, 18) that suggested the phosphorylation of ERK (MAPK) after Hcy treatment in vascular smooth muscle cells (VSMCs) and that mesangial cells reached a maximum 10 -100 M concentration within 10 -20 min.
To determine whether ERK is activated via the Raf-MEK-MAPK pathway, we used a specific inhibitor for MEK. PD-98059 and U0126 significantly reduced ERK activation, suggesting that Hcy-mediated ERK activation occurred in a MEKdependent manner. MAPK (ERK) is a key point of convergence in signaling for many cell surface receptors, including receptor PTKs and GPCRs (2, 8) . Hcy may activate the growth factor signal transduction pathway, resulting in atherosclerosis (18) . Various growth factor and G proteinlinked agonists initiate the release of Ca 2ϩ from intracellular stores. Recently, capacitative Ca 2ϩ entry, which is also applicable to Hcy-mediated Ca 2ϩ transients, has been suggested to occur via activation of one or more PTKs (23) . Receptor and nonreceptor PTKs constitute the initiators of the ERK signaling pathway (1, 35) . Others have suggested that Ca 2ϩ is involved in ERK activation induced by hormones acting on GPCRs in hepatocytes (27) . Hcy and its metabolites are known to interact with molecular targets such as neurotransmitter receptors, channels, or transporters and are potent and effective agonists at several rat metabotropic glutamate receptors (mGluRs). Moreover, mGluRs are candidate GPCRs for intracellular signal transduction by Hcy (38) . G q has also been implicated in the regulation of Ca 2ϩ , PKC, and PTKs. However, the mechanisms by which Hcy affects GPCR coupling to G proteins are incompletely understood. We evaluated the role of PTKs and GPCRs in Hcy-induced ERK activation in MVECs. We found that the inhibitors for PTKs and GPCRs, i.e., genistein and PTX, abrogated Hcy-induced ERK activation. PTX data suggested the involvement of G i , although G q also has been shown to regulate Ca 2ϩ , PKC, and PTKs. Previously, we demonstrated that Hcy induced an increase in [Ca 2ϩ ] i in VSMCs that was ameliorated by genistein (30) . This suggests the involvement of protein G i -sensitive GPCRs in Hcy-induced ERK activation, which involves Ca 2ϩ , PKC, and PTKs. These findings imply that Hcy-stimulated cell surface receptors initiate a signal transduction pathway and lead to ERK activation. We sought to validate the role played by Ca 2ϩ in Hcy-induced ERK activation.
We observed that Hcy-induced ERK activation was repressed by incubating the cells with a cell-permeable intracellular Ca 2ϩ chelator (BAPTA-AM) and exposure of cells to ionomycin-activated ERK, which imply the involvement of Ca 2ϩ in ERK activation (Fig. 6 ). This finding is in accordance with the results reported by Ingram et al. (18) , which showed the involvement of Ca 2ϩ in Hcy-induced ERK activation in mesangial cells. Furthermore, we noticed that Tg, a sarco(endo)plasmic reticulum Ca 2ϩ -ATPase blocker, activated ERK, which was abrogated by treatment with BAPTA-AM and genistein. These findings suggested that the PTK pathway is involved in Hcy-induced ERK activation, which is mediated by intracellular Ca 2ϩ pool depletion. These observations are in agreement with the finding in rat liver epithelial WB cells that Ca 2ϩ store depletion increases ERK phosphorylation via the PTK pathway (24) .
In cardiac myocytes, activation of ERK (MAPK) was blocked by NAC, implicating a role for oxidative stress in signaling events (4) . In previous studies of mesangial cells, oxidative stress was not involved in Hcy-induced ERK activation (6). We found that treatment of the cells with NAC and SOD reduced Hcy-mediated ERK phosphorylation (Fig. 4) . This disparity might be attributed to differences in cell type, doses of Hcy used, and the mode of treatment applied.
Folic acid administration reduces the risk of atherosclerosis caused by elevated levels of Hcy. We sought to determine the effect of folate supplementation on Hcy-induced ERK activation. This report is the first to describe abrogation of Hcyinduced ERK phosphorylation, which was found to be MEK dependent, upon treatment of MVECs with folate (Fig. 4) . Few reports have suggested a role of folate in ERK activation. Folate acts as a chemoattractant and induces ERK2 activation in Dictyostelium discoideum (20) .
Hcy induced the activation of PKC and stimulated c-Fos in murine macrophages (3) . Several lines of evidence indicate that PKC activates the MAPK signal transduction pathway. PKC played an important role in mediating ERK activation and subsequent DNA synthesis in intestinal epithelial cells in response to ANG II (9) . PKC is a multigene family composed of at least 12 distinct isoforms and is an important constituent of the signaling pathway triggered by mitogen through cell surface receptors. In the present study, we observed that treatment with staurosporine reduced Hcy-mediated ERK activation (Fig. 7) , which suggests that Hcy-stimulated cell surface receptors initiated signal transduction involving PKC and led to ERK activation. Because Hcy induced alterations in Ca 2ϩ dynamics, we suspected the involvement of the Ca 2ϩ -dependent PKC isoform. We have shown that Gö6976, a specific inhibitor of PKC-␣, abrogated Hcy-induced ERK activation in MVECs (Fig. 7C) . Furthermore, to validate the involvement of Ca 2ϩ -dependent PKC, we downregulated PKC by treating cells with PBDu for 24 h and evaluated the Hcy-induced ERK phosphorylation and PKC-␣ expression, which was found to be suppressed (Fig. 7C) . Additional information is required to confirm which other isoforms of PKC are A: serum-starved MVECs either were left untreated or were pretreated for 30 min with 0.1% DMSO; 1 M staurosporine; and 100 nM PMA, an agonist for PKC; followed by 30-min treatment with 10 M Hcy. Top gel: ERK1/2 phosphorylation was measured using Western blot analysis of cell lysates; bottom gel: membranes were reprobed for total ERK2. Bar graphs below gels demonstrate ERK1/2 activation (increase relative to control). Ca 2ϩ -dependent PKC was involved in Hcy-induced ERK activation. B: serum-starved MVECs either were left untreated or were pretreated for 24 h with 100 nM PBDu for 30 min with 1 M Gö6976, an inhibitor of Ca 2ϩ -dependent PKC, and for 30 min with PD-98059, followed by 30-min treatment with 10 M Hcy Bottom gel: ERK1/2 phosphorylation was measured using Western blot analysis of cell lysates; top gel: membranes were reprobed for total ERK2. The density of the bands was determined and quantified for the ERK1/2 activation (increase relative to control). C: cells treated with 100 nM PBDu for 24 h. induced by Hcy treatment and are involved in the ERK signaling pathway.
MMPs play an important role in the degradation of the ECM, leading to vascular pathology. Previously, we showed that Hcy induces the activation of MMP-9 in MVECs; however, the regulatory mechanisms remain to be elucidated fully. The promoter region of the MMP-9 gene contains AP-1 sites, thus implying a role for the MAPK signaling pathway in the regulation of MMP-9. Different studies of various cell types have suggested a role for ERK activation in MMP-9 induction (26, 34, 42) .
Our data demonstrate that Hcy increased the activity of MMP-9 in MVECs. Treatment with the ERK1/2 pathway inhibitor PD-98059 resulted in inhibition of MMP-9 induction (Fig. 8) , which suggested that Hcy-induced MMP-9 is regulated by the ERK pathway. It is still possible that other members of the MAPK family, i.e., JNK/SAPK and p38, are involved in MMP-9 regulation. In fact, Hcy is capable of activating JNK (7) and p38 (10) .
In the present study, we have shown that the Hcy-induced ERK activation involved PKC and oxidative stress transduction pathways. Our aim was to investigate whether these transduction pathways are involved in Hcy-induced MMP-9 upregulation. Evidence from different cell systems showed that oxidative stress is involved in the induction of MMP-9. We observed that inhibiting ROS generation by NAC treatment significantly inhibited the activation of MMP-9 in MVECs. These observations suggest that the oxidative transduction pathway is important for Hcy-mediated MMP-9 induction. Hcy-induced MMP-9 activation was blocked by treating the cells with staurosporine, a PKC inhibitor, which suggested the role of the PKC transduction pathway in MMP-9 regulation. LPS induced MMP-9 secretion in part via sequential activation of PKC and the ERK1/2-dependent pathway in rat primary astrocytes (22) .
In conclusion, we have demonstrated that Hcy triggers PTX-sensitive GPCRs, which initiate signal transduction involving PTKs, Ca 2ϩ -dependent PKC, and oxidative stress, leading to ERK1/2 activation. Furthermore, we have presented evidence that Hcy-mediated MMP-9 induction is regulated by the ERK1/2 signaling pathway in cultured MVECs (Fig. 9) .
